Mice With Enhanced CGRP Signaling Resist Standard Migraine Treatments for Motion Sensitivity
Mice engineered with enhanced CGRP signaling showed increased motion sensitivity and resistance to migraine treatments, modeling vestibular migraine.
Quick Facts
What This Study Found
The nestin/hRAMP1 mice showed heightened sensitivity to CGRP's effects at lower doses compared to normal mice. They exhibited increased motion-induced thermoregulation changes (a surrogate for nausea) and greater postural sway (a measure of balance dysfunction). Male nestin/hRAMP1 mice specifically showed increased sway not seen in male controls.
Migraine blocker experiments were challenging to interpret, but the data suggests olcegepant (a CGRP receptor antagonist) could not reverse CGRP-induced or endogenous changes in these mice. Rizatriptan (a triptan) was ineffective in both the engineered mice and controls.
The authors propose this mouse model represents treatment-resistant migraine with vestibular features.
Key Numbers
- nestin/hRAMP1 mice: enhanced sensitivity to CGRP at lower doses
- Increased motion-induced thermoregulation changes (nausea surrogate)
- Greater postural sway dynamic range
- Male mice showed increased sway vs male controls
- Olcegepant: unable to reverse CGRP-related symptoms
- Rizatriptan: ineffective in both groups
How They Did This
Researchers used nestin/hRAMP1 transgenic mice that express elevated human RAMP1 in the nervous system, enhancing CGRP signaling. They measured motion sensitivity using motion-induced thermoregulation (a nausea surrogate) and postural sway using center of pressure assays. They tested olcegepant (CGRP receptor antagonist) and rizatriptan (5-HT1B/1D agonist) as migraine treatments.
Why This Research Matters
Vestibular migraine (migraine with dizziness and motion sensitivity) affects about 1% of the general population and is poorly understood. Many patients do not respond well to standard migraine treatments. A mouse model that mimics treatment-resistant vestibular migraine could help researchers understand why some patients fail therapy and test new drug candidates.
The Bigger Picture
Vestibular migraine (migraine with dizziness) affects about 1% of the population and is poorly understood. This mouse model could help researchers develop targeted treatments for patients who don't respond to standard CGRP-blocking drugs.
What This Study Doesn't Tell Us
Mouse behavioral surrogates for nausea and dizziness are imperfect. The authors note the migraine blocker experiments were challenging to interpret. RAMP1 overexpression is a genetic model that may not match the complex neurobiology of human vestibular migraine. Sample sizes for behavioral assays are typically small. Sex differences were observed but not fully explained.
Questions This Raises
- ?Why are standard CGRP blockers less effective in this enhanced signaling model?
- ?Could higher doses of CGRP antibodies overcome the resistance?
Trust & Context
- Key Stat:
- Resistant to migraine blockers Mice with enhanced CGRP signaling did not respond as expected to standard anti-CGRP migraine treatments
- Evidence Grade:
- Rated preliminary: transgenic mouse model providing mechanistic insights, but mouse behavioral surrogates for nausea and dizziness are imperfect.
- Study Age:
- Published in 2024. Adds to a growing body of research on CGRP's role in vestibular migraine.
- Original Title:
- Human RAMP1 overexpressing mice are resistant to migraine therapies for motion sensitivity.
- Published In:
- PloS one, 19(12), e0313482 (2024)
- Authors:
- Rahman, Shafaqat M(4), Guo, Linda Jia, Minarovich, Carissa, Moon, Laura, Guo, Anna, Luebke, Anne E
- Database ID:
- RPEP-09110
Evidence Hierarchy
Frequently Asked Questions
What is vestibular migraine?
A type of migraine that includes dizziness, motion sensitivity, and balance problems, affecting about 1% of the general population.
Why don't some migraine drugs work for vestibular migraine?
This study suggests enhanced CGRP signaling may overwhelm standard drug doses, explaining treatment resistance in some patients.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09110APA
Rahman, Shafaqat M; Guo, Linda Jia; Minarovich, Carissa; Moon, Laura; Guo, Anna; Luebke, Anne E. (2024). Human RAMP1 overexpressing mice are resistant to migraine therapies for motion sensitivity.. PloS one, 19(12), e0313482. https://doi.org/10.1371/journal.pone.0313482
MLA
Rahman, Shafaqat M, et al. "Human RAMP1 overexpressing mice are resistant to migraine therapies for motion sensitivity.." PloS one, 2024. https://doi.org/10.1371/journal.pone.0313482
RethinkPeptides
RethinkPeptides Research Database. "Human RAMP1 overexpressing mice are resistant to migraine th..." RPEP-09110. Retrieved from https://rethinkpeptides.com/research/rahman-2024-human-ramp1-overexpressing-mice
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.